ArticleInternational journal of clinical oncology2026
Real-world clinical utility and challenges of comprehensive genomic profiling for advanced solid tumors in a community health institution.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundComprehensive genomic profiling (CGP) tests were approved, and opportunities to consider tissue-agnostic targeted therapies based on molecular tumor profiling have increased even in the community-based medicine practice. However, low treatment success rates and regional disparities in access to investigational drugs remain significant challenges. This retrospective study aimed to evaluate the drug accessibility rate and prognostic impact of CGP testing for advanced or metastatic solid tumors at Hiroshima Prefectural Hospital, a facility located far from clinical trial sites.
methodsWe analyzed data from 378 patients who underwent CGP testing between June 2019 and June 2024. Patient characteristics, specimen details, molecular tumor board (MTB) assessments of CGP results, and clinical courses were collected. Overall survival (OS) after MTB assessment was evaluated using the Kaplan-Meier method and log-rank test.
resultsThe median patient age was 69 (range: 10-92) years. Lung cancer was the most common cancer type, affecting 105 patients (27.8%). CGP testing identified one or more gene mutations in 356 patients (94.2%), of whom 248 (65.6%) harbored druggable genomic alterations, and 37 (9.8%) received genomically matched therapy. Among them, 27 (73%) received approved drugs. The OS advantage observed in patients who received genomically matched therapy was statistically significant. Among patients who did not receive genomically matched therapy, approximately 20% expressed willingness to participate in clinical trials.
conclusionsThese findings demonstrate the clinical utility of CGP testing in local medical facilities; however, the high proportion of approved drugs among genomically matched treatments highlights significant barriers to clinical trial participation.
Indexed as
Identifiers
41572061What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.